The FINANCIAL — EnterNext, the Euronext subsidiary designed to promote and grow the market for SMEs, today welcomed Kiadis Pharma on the Amsterdam and Brussels market of Euronext.
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company is committed to developing innovative and potentially life‑saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.
The total offering of Kiadis Pharma was valued at € 32.7 million. After opening, the market price was € 12.50 per share. Based on the opening price, the total market capitalization of the company was approximately € 166.4 million, according to Euronext.
Manfred Rüdiger, CEO Kiadis Pharma, said: “We are delighted to have joined Euronext on July 2. Kiadis Pharma’s IPO received significant interest from local, European and US investors and now we intend to advance our pipeline of products that will potentially save the lives of thousands of blood cancer and inherited blood disorder patients.”
“We would like to congratulate Kiadis Pharma on its successful IPO”, said Maurice van Tilburg, CEO of Euronext Amsterdam. “It is great to see another biopharmaceutical company list on our markets. This transaction confirms the stockmarket’s appeal for biotech companies, allowing them to raise the capital they need to step up the pace of development.“
Vincent van Dessel, CEO Euronext Brussels, added: “We are delighted to welcome Kiadis Pharma today to Euronext, Europe’s most active market for life sciences. Through EnterNext we are fully committed to support the company in its objective to become a leading biopharmaceutical company focused on developing and commercialising therapeutic products in cell-based immunotherapy.”
To celebrate the listing, CEO of Kiadis Pharma Manfred Rüdigersounded the gong in Amsterdam to open trading on Euronext’s markets.